Ajanta Pharma Share News - Latest Updates, Live News & More

Latest news about Ajanta Pharma

Ajanta Pharma Clarifies No Involvement in Restaurant Brands Asia Acquisition Deal 3 hrs ago Today

Ajanta Pharma Limited has clarified to stock exchanges that it is not involved in the acquisition of Restaurant Brands Asia, contrary to media reports. The company stated that while Lenexis Foodworks Pvt. Ltd., managed by a section of its promoter group, is independently pursuing the acquisition, Ajanta Pharma and its management have no involvement in the transaction. The clarification was submitted under SEBI regulations on February 10, 2026.

Ajanta Pharma Vests 4,300 Stock Appreciation Rights and Cancels 800 Employee Stock Options 10 days ago

Ajanta Pharma Reports 16% Growth in Q3 Consolidated Net Profit to ₹2.7 Billion 10 days ago

Ajanta Pharma Clarifies No Interest in Restaurant Brands Asia Acquisition Jan 20, 2026

Ajanta Pharma Establishes Wholly Owned Subsidiary in Ireland for Pharmaceutical Operations Jan 13, 2026

More news about Ajanta Pharma

13Jan 26

Ajanta Pharma Establishes New Subsidiary in Ireland

Ajanta Pharma has created a new subsidiary in Ireland named Ajanta Pharma Ireland, representing a strategic expansion into the European market. This move strengthens the company's international presence and could enhance its access to European pharmaceutical markets through improved operational structure.

12Jan 26

Ajanta Pharma schedules Q3FY26 earnings conference call for January 30, 2026

Ajanta Pharma announced an earnings conference call for January 30, 2026 at 16:30 hrs IST to discuss Q3FY26 unaudited financial results. The company filed this under SEBI Regulation 30 on January 12, 2026. Multiple dial-in options include international toll-free numbers for USA, UK, Hong Kong, and Singapore, with Diamond pass registration for faster access. Call playback will be available on the company website within 120 minutes.

30Dec 25

Motilal Oswal Maintains 'Buy' Rating on Ajanta Pharma with Target Price ₹3,145

Motilal Oswal has reaffirmed its 'Buy' rating on Ajanta Pharma with a specific target price of ₹3,145, emphasizing the company's strategic initiatives across key markets in India, Asia, and Africa. The brokerage firm expects the pharmaceutical company to sustain robust industry outperformance through its focused approach in branded generics markets.

23Dec 25

Ajanta Pharma Signs In-licensing Agreement With Biocon For Semaglutide Supply

Ajanta Pharma has entered into a strategic in-licensing agreement with Biocon Limited for Semaglutide supply across 26 countries, securing exclusive marketing rights in 23 markets and semi-exclusive rights in 3 markets. The GLP-1 receptor agonist is expected to launch in late 2026 or early 2027, leveraging Ajanta Pharma's strong presence across Africa, Middle East and Central Asia regions.

13Nov 25

Ajanta Pharma Promoters Release Pledge on 4.2 Lakh Shares

Ajanta Pharma has reported pledge releases by two promoters - Ravi Agrawal releasing 10,50,000 shares due to excess pledge and Aayush Agrawal releasing 4,20,255 shares citing upward movement in market price. The disclosures were made to BSE and NSE under SEBI regulations, demonstrating the company's commitment to transparency and regulatory compliance.

03Nov 25

Ajanta Pharma Sets November 10 as Record Date for First Interim Dividend

Ajanta Pharma has declared a first interim dividend of Rs. 28 per share for FY 2026, with a record date of November 10, 2025. The total dividend payout amounts to Rs. 349.82 crore. This announcement follows strong Q2 FY 2026 results, with revenue up 14% to Rs. 1,354 crore and PAT growing 20% to Rs. 260 crore. The company reported growth across all segments, with US Generics showing a significant 48% increase. Ajanta's performance in key therapeutic areas outpaced the Indian Pharmaceutical Market growth.

03Nov 25

Ajanta Pharma Reports 20% Profit Growth in Q2 FY 2026, Declares Rs. 28 Interim Dividend

Ajanta Pharma Limited announced robust Q2 FY 2026 results, with revenue from operations increasing 14% to Rs. 1,354.00 cr. Profit After Tax (PAT) grew 20% to Rs. 260.00 cr. The US Generics segment showed remarkable 48% growth. The company's branded generics business, accounting for 72% of total revenue, grew by 8%. Ajanta outperformed the Indian Pharmaceutical Market in key therapeutic areas. The Board approved a first interim dividend of Rs. 28 per share. The company maintains a strong product pipeline with 50 commercialized ANDAs and 22 awaiting US FDA approval.

24Oct 25

Ajanta Pharma Board to Consider First Interim Dividend for FY 2025-26

Ajanta Pharma's Board of Directors will meet on November 3, 2025, to consider declaring the first interim dividend for FY 2025-26. They will also review unaudited financial results for Q2 and H1 FY 2025-26. If a dividend is declared, November 10, 2025, may be set as the record date for shareholder eligibility. The meeting aligns with regulatory requirements and will provide insights into the company's financial health and shareholder return policies.

03Oct 25

Ajanta Pharma Promoter Aayush Agrawal Creates Multiple Fresh Pledges

Ajanta Pharma promoter Aayush Agrawal Trust has created multiple fresh pledges in December 2025, including the latest disclosure of 1,27,660 shares for loan increase and an earlier pledge of 16,02,500 shares for bank guarantee purposes, continuing the pattern of active promoter financing activities.

10Sept 25

Ajanta Pharma Promoter Releases Pledge on 130,000 Shares for Refinancing

Ravi Agrawal, a key promoter of Ajanta Pharma Limited, has released a pledge on 130,000 shares for refinancing purposes. The company has filed the necessary regulatory disclosures with both BSE and NSE in compliance with SEBI regulations. This action may be viewed positively by the market as it could indicate the promoter's confidence in the company's financial stability.

19Aug 25

IT Department Raids Ajanta Pharma Premises

The Income Tax Department has conducted raids at Ajanta Pharma's premises. While the raid has been confirmed, specific details about its scope, duration, or reasons remain undisclosed. This development has raised concerns in the pharmaceutical sector, potentially affecting Ajanta Pharma's operations, reputation, and market standing. Stakeholders are awaiting further information about the nature of the investigation and its possible impact on the company's business operations.

28Jul 25

Ajanta Pharma Reports Robust Q1 Results with 14% Revenue Growth

Ajanta Pharma announced robust Q1 financial results, with consolidated revenue increasing 14% to ₹1,303.00 crore. Net profit rose 4% to ₹255.00 crore, while EBITDA grew 6% to ₹351.00 crore. The branded generics segment, accounting for 73% of total revenue, grew by 9% to ₹941.00 crore. US generics showed exceptional growth of 36%, reaching ₹310.00 crore. The company launched 8 new products in India and 12 in emerging markets during the quarter.

14Jul 25

Ajanta Pharma: Significant Block Trade of 3.16 Lakh Shares on NSE

A significant block trade of approximately 3.16 lakh (315,631) shares of Ajanta Pharma was executed on the National Stock Exchange (NSE). The transaction occurred at Rs. 2,619.50 per share, totaling Rs. 82.68 crore. This large-scale trade indicates substantial market interest in the pharmaceutical company's stock, potentially impacting its short-term price and trading volumes.

02May 25

Ajanta Pharma Q4 FY25: Revenue Grows, Margins Shrink Amid Market Challenges

Ajanta Pharma's Q4 FY25 results show 11% YoY revenue growth to Rs 11.70 billion and 11.10% PAT increase to Rs 2.30 billion. EBITDA grew 6.80% YoY to Rs 2.97 billion, but margins contracted. Systematix maintains 'Buy' rating with revised target price. Results published in Business Standard and Navakal on May 1, 2025.

30Apr 25

Ajanta Pharma Reports 11% Growth in Q4 Profit and Revenue, Margin Contracts

Ajanta Pharma Limited announced strong Q4 FY2025 results with revenue up 11% to ₹1,170.00 crore and net profit increasing 12.50% to ₹225.00 crore. EBITDA grew 6.83% to ₹297.00 crore, though the EBITDA margin slightly decreased. The company distributed ₹700.00 crore to shareholders in FY2025, representing 76% of PAT. An earnings conference call is scheduled for April 30, 2025, to discuss the results further.

21Mar 25

Ajanta Pharma Joins FTSE All World Index, Expands Manufacturing Capacity

Ajanta Pharma has been added to the FTSE All World Index, potentially attracting $23.80 million in foreign investment. The company also announced plans to triple its liquid formulation production capacity from 6 million to 18 million bottles annually at its Pithampur site. This Rs. 92 crore expansion project, funded through internal accruals, is expected to be completed by Q1 FY 2026.

20Mar 25

Ajanta Pharma to Invest ₹92 Crore in Pithampur Facility Expansion

Ajanta Pharma Limited plans to invest ₹92 crore to expand its Pithampur manufacturing site, adding a new liquid formulation facility. The expansion will increase production capacity from 6 million to 18 million bottles per annum on a single shift basis. The project, financed through internal accruals, is set to be completed by Q1 FY 2026. This strategic move aims to meet growing global demand and alleviate current production pressures, with the existing facility operating at 175% utilization.